1 Sumida, Y. & Yoneda, M. Current and future pharmacological therapies for NAFLD/NASH. Journal of gastroenterology53, 362-376 (2018).
2 Stefan, N., Häring, H.-U. & Cusi, K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. The lancet Diabetes & endocrinology7, 313-324 (2019).
3 Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology64, 73-84 (2016).
4 Eguchi, Y. et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. Journal of gastroenterology47, 586-595 (2012).
5 Ahmed, A., Wong, R. J. & Harrison, S. A. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clinical Gastroenterology and Hepatology13, 2062-2070 (2015).
6 Castera, L., Vilgrain, V. & Angulo, P. Noninvasive evaluation of NAFLD. Nature reviews Gastroenterology & hepatology10, 666-675 (2013).
7 Pais, R. et al. NAFLD and liver transplantation: current burden and expected challenges. Journal of hepatology65, 1245-1257 (2016).
8 Yoshitaka, H. et al. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: a post hoc analysis of a cohort study. Medicine96 (2017).
9 Brouwers, M. C., Simons, N., Stehouwer, C. D. & Isaacs, A. Non-Alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia, 1-8 (2020).
10 Kotronen, A. & Yki-Järvinen, H. Fatty liver: a novel component of the metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology28, 27-38 (2008).
11 Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine363, 1341-1350 (2010).
12 Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature reviews Gastroenterology & hepatology10, 330 (2013).
13 Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P. & Loria, P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver disease47, 181-190 (2015).
14 Neuschwander‐Tetri, B. A. et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology52, 913-924 (2010).
15 Kaps, L. et al. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterology Journal, 2050640620944098 (2020).
16 Armstrong, M. J., Adams, L. A., Canbay, A. & Syn, W. K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology59, 1174-1197 (2014).
17 Ji, D. et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. Journal of Hepatology (2020).
18 Roca-Fernandez, A. et al. HIGH LIVER FAT ASSOCIATES WITH HIGHER RISK OF DEVELOPING SYMPTOMATIC COVID-19 INFECTION-INITIAL UK BIOBANK OBSERVATIONS. medRxiv (2020).
19 Chen, V. L. et al. Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19. Digestive diseases and sciences, doi:10.1007/s10620-020-06618-3 (2020).
20 Estep, J., Birerdinc, A. & Younossi, Z. Non-invasive diagnostic tests for non-alcoholic fatty liver disease. Current molecular medicine10, 166-172 (2010).
21 Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome.(Clinical report). eLife7, doi:10.7554/eLife.34408 (2018).
22 Mokry, L. E., Ahmad, O., Forgetta, V., Thanassoulis, G. & Richards, J. B. Mendelian randomisation applied to drug development in cardiovascular disease: a review. Journal of medical genetics52, 71-79 (2015).
23 Mohammadi-Shemirani, P. et al. A Mendelian randomization-based approach to identify early and sensitive diagnostic biomarkers of disease. Clinical chemistry65, 427-436 (2019).
24 Ritchie, S. C. et al. Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases. BioRxiv (2019).
25 Jongstra-Bilen, J. et al. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. 203, 2073-2083, doi:10.1084/jem.20060245 %J The Journal of Experimental Medicine (2006).
26 Mounier, N. & Kutalik, Z. bGWAS: an R package to perform Bayesian Genome Wide Association Studies. Bioinformatics (2020).
27 Liu, Z. et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. Journal of Hepatology (2020).
28 Kettunen, J. et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nature communications7, 1-9 (2016).
29 Consortium, G. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science348, 648-660 (2015).
30 Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature558, 73-79 (2018).
31 Kryuchkova-Mostacci, N. & Robinson-Rechavi, M. A benchmark of gene expression tissue-specificity metrics. Briefings in bioinformatics18, 205-214 (2017).
32 Initiative, C.-H. G. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. European Journal of Human Genetics, 1 (2020).
33 Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature genetics40, 1461-1465 (2008).
34 Emdin, C. A. et al. A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS genetics16, e1008629 (2020).
35 Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nature genetics46, 352-356 (2014).
36 Parisinos, C. A. et al. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. Journal of Hepatology (2020).
37 Wu, J., Yang, Y., Wang, X., Zhou, X. & Zhang, C. Modified triple pelvic osteotomy for adult symptomatic acetabular dysplasia: clinical and radiographic results at midterm follow-up. Journal of orthopaedic surgery and research13, 1-7 (2018).
38 Chambers, J. C. et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature genetics43, 1131-1138 (2011).
39 Waterworth, D. M. et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology30, 2264-2276 (2010).
40 Scuteri, A. et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet3, e115 (2007).
41 Genetics, M. I. & Investigators, C. E. C. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. The New England journal of medicine374, 1134 (2016).
42 Lauridsen, B. K. et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. European Heart Journal39, 385-393 (2018).
43 Liu, D. J. et al. Exome-wide association study of plasma lipids in> 300,000 individuals. Nature genetics49, 1758-1766 (2017).
44 Ling, S. & Shu-zheng, L. Association between non-alcoholic fatty liver disease and coronary artery disease severity. Chinese medical journal124, 867-872 (2011).
45 Friedrich-Rust, M. et al. Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study. PloS one12, e0186720 (2017).
46 Mahajan, A. et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nature genetics50, 559-571 (2018).
47 Grzych, G. et al. Plasma BCAA changes in Patients with NAFLD are Sex Dependent. The Journal of Clinical Endocrinology & Metabolism105, dgaa175 (2020).
48 Lovric, A. et al. Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. Scientific reports8, 1-14 (2018).
49 Lim, S., Taskinen, M. R. & Borén, J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obesity Reviews20, 599-611 (2019).
50 Jin, R. et al. Amino acid metabolism is altered in adolescents with nonalcoholic fatty liver disease—An untargeted, high resolution metabolomics study. The Journal of pediatrics172, 14-19. e15 (2016).
51 Lake, A. D. et al. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino acids47, 603-615 (2015).
52 Sliz, E. et al. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Human molecular genetics27, 2214-2223 (2018).
53 Andersson, S. M., Salaspuro, M. & Ohisalo, J. J. Metabolic basis of hypertyrosinemia in liver disease. Gastroenterology82, 554-557 (1982).
54 Knapen, M. F. et al. Plasma glutathione S-transferase alpha 1-1: a more sensitive marker for hepatocellular damage than serum alanine aminotransferase in hypertensive disorders of pregnancy. American journal of obstetrics and gynecology178, 161-165 (1998).
55 Shimazawa, R. & Ikeda, M. Safety information in drug labeling: a comparison of the USA, the UK, and Japan. Pharmacoepidemiology and drug safety22, 306-318 (2013).
56 Visinoni, S. et al. The role of liver fructose-1, 6-bisphosphatase in regulating appetite and adiposity. Diabetes61, 1122-1132 (2012).
57 Kroschwald, P. et al. Occurrence of the erythroid cell specific arachidonate 15-lipoxygenase in human reticulocytes. 160, 954-960 (1989).
58 Lieber, C. S. Metabolism of alcohol. Clinics in liver disease9, 1-35 (2005).
59 Stender, S. et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nature genetics49, 842-847 (2017).
60 Ponsford, M. J. et al. Cardiometabolic Traits, Sepsis and Severe COVID-19: A Mendelian Randomization Investigation. Circulation, doi:10.1161/CIRCULATIONAHA.120.050753 (2020).
61 Namjou, B. et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC medicine17, 135 (2019).
62 Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nature genetics50, 1335-1341 (2018).
63 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics26, 2190-2191 (2010).
64 Bowden, J. et al. A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomization. Statistics in medicine36, 1783-1802 (2017).
65 Verbanck, M., Chen, C.-y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nature genetics50, 693-698 (2018).
66 Wright, F. A. et al. Heritability and genomics of gene expression in peripheral blood. Nature genetics46, 430-437 (2014).
67 Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome biology11, 1-9 (2010).
68 Yanai, I. et al. Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics21, 650-659 (2005).
69 Zheng, J. et al. PhenoSpD: an integrated toolkit for phenotypic correlation estimation and multiple testing correction using GWAS summary statistics. GigaScience7, doi:10.1093/gigascience/giy090 (2018).